Skip to search formSkip to main contentSkip to account menu

CAT-8015

Known as: Anti-CD22 Immunotoxin CAT-8015, GCR-8015, Immunotoxin CAT-8015 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

immunotoxin HA22

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia
Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving… 
2018
2018
Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
Acute Lymphoblastic Leukemia (ALL) remains the most frequent cause of cancer-related mortality in children and novel therapies… 
Review
2015
Review
2015
Immunoconjugates in the management of hairy cell leukemia.
Highly Cited
2012
Highly Cited
2012
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
PURPOSE To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox… 
2012
2012
Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).
2503^ Background: The anti-CD22 recombinant immunotoxin moxetumomab pasudotox, also known as HA22 or CAT-8015, was recently… 
Review
2011
Review
2011
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
Standard treatment for hairy cell leukemia (HCL) is markedly effective, but the constant decrease in disease-free survival… 
2010
2010
Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.
6523 Background: CAT-8015 (HA22) contains the Fv domains of the anti-CD22 Mab RFB4 and truncated pseudomonas exotoxin, inducing… 
Highly Cited
2009
Highly Cited
2009
CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Purpose: To compare the in vitro and in vivo efficacy of CAT-8015, a second-generation recombinant immunotoxin composed of… 
2009
2009
Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.
2006
2006
Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies
3728 Immunotoxins are a class of anti-cancer therapies that are hybrid proteins composed of a tumor-targeting monoclonal antibody… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)